Literature DB >> 1552831

Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes.

K Veeraragavan1, K Sethumadhavan, C Y Bowers.   

Abstract

The synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP, Growth Hormone-Releasing Peptide), has no structural similarities with any of the GH-releasing peptides known and its action in releasing GH is by a complementary but yet not clearly defined action on the pituitary as well as hypothalamus. Therefore, in vitro studies have been performed to demonstrate and characterize GHRP binding sites on peripheral membranes of both porcine pituitary and hypothalamus. The membrane binding sites were specific, reversible, saturable and time, temperature, pH and concentration dependent under optimum binding assay conditions. The maximum specific binding was observed between pH 5.0 and 6.0. In the presence of Ca2+ and Mg2+ ions, with or without chelating agents there was a significant reduction in the specific binding. Scatchard analysis of these binding sites using increasing doses of unlabeled GHRP revealed a single low affinity site with a 2.1 x 10(-5) M and 1.7 x 10(-5) M and a maximum number of sites of 10 nmol/mg protein and 5 nmol/mg protein for pituitary and hypothalamus, respectively. It is also observed that (D-Lys3)-GHRP, substance P antagonists and growth hormone-releasing factor analog were potent inhibitors of GHRP binding in both tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552831     DOI: 10.1016/0024-3205(92)90457-z

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.

Authors:  G S Tannenbaum; C Y Bowers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Authors:  E Arvat; L Di Vito; F Lanfranco; F Broglio; R Giordano; A Benso; G P Muccioli; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

4.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

Review 5.  Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.

Authors:  Martha A Schalla; Andreas Stengel
Journal:  Curr Diab Rep       Date:  2019-09-10       Impact factor: 4.810

6.  Antagonism of ghrelin receptor reduces food intake and body weight gain in mice.

Authors:  A Asakawa; A Inui; T Kaga; G Katsuura; M Fujimiya; M A Fujino; M Kasuga
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.